作者: Andreas M Pleil , Karl J Kreder , Pat Ray Reese , Con J Kelleher , Somali Misra Burgess
DOI:
关键词:
摘要: Objective: To compare the health-related quality of life (HRQoL) overactive bladder (OAB) patients following treatment with tolterodine extendedrelease (ER) 4 mg once daily versus placebo. Study Design: Multinational, placebo-controlled, randomized, double-blind 12-week study. Population: Patients urinary frequency (≥8 micturitions/24 hours over a 7-day period), urge incontinence (≥5 episodes/week), and symptoms OAB for at least 6 months were eligible inclusion. (81% female) received oral therapy ER (n = 507) or placebo 508) 12 weeks. Outcomes Measured: HRQoL was assessed using King’s Health Questionnaire (KHQ) Medical Short Form 36-item questionnaire (SF-36). also rated their condition. Assessments performed baseline end treatment. Results: At treatment, KHQ domains selected priori as primary points (incontinence impact role limitations) significantly improved (P ≤ .001) ER. Domains secondary (physical limitations, sleep energy, severity [coping] measures, symptom severity) .006) The group had decreased statistically significant improvements in patient rating control compared No differences detected SF-36. Conclusion: Many aspects HRQoL, measured by KHQ, showed improvement These consistent clinical efficacy benefits. receiving experienced overall